Edgar Jacoby

Edgar Jacoby

Auto-generated profile, based on publicly available information

Edgar Jacoby

Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Drug Discovery Today
Verified
Journal Article
Closed access
EJEdgar Jacoby
Edgar Jacoby
GTGary Tresadern
Gary Tresadern
SBScott Bembenek
Scott Bembenek
BWBerthold Wroblowski
Berthold Wroblowski
CBChristophe Buyck
Christophe Buyck
HVHerman van Vlijmen
Herman van Vlijmen

11 May 2016 in MedChemComm
Verified
Journal Article
Open access
PDF file
DDD. Digles
D. Digles
BZBarbara Zdrazil
Barbara Zdrazil
JNJ.-M. Neefs
J.-M. Neefs
HVH. Van Vlijmen
H. Van Vlijmen
CHC. Herhaus
C. Herhaus
EJE. Jacoby
E. Jacoby
Phenotypic screening is in a renaissance phase and is expected by many academic and industry leaders to accelerate the discovery of new drugs for new biology. Given that phenotypic screening is per definition target agnostic, the emphasis of in silico and in vitro follow-up work is on the exploration of possible molecular mechanisms and efficacy targets underlying the biological processes interrogated by the phenotypic screening experiments. Herein, we present six exemplar computational protocols for the interpretation of cellular phenotypic screens based on the integration of compound, target, pathway, and disease data established by the IMI Open PHACTS project. The protocols annotate phenotypic hit lists and allow follow-up experiments and mechanistic conclusions. The annotations included are from ChEMBL, ChEBI, GO, WikiPathways and DisGeNET. Also provided are protocols which select from the IUPHAR/BPS Guide to PHARMACOLOGY interaction file selective compounds to probe potential targets and a correlation robot which systematically aims to identify an overlap of active compounds in both the phenotypic as well as any kinase assay. The protocols are applied to a phenotypic pre-lamin A/C splicing assay selected from the ChEMBL database to illustrate the process. The computational protocols make use of the Open PHACTS API and data and are built within the Pipeline Pilot and KNIME workflow tools.

8 November 2017 in Molecular Informatics
Verified
Journal Article
Closed access
PDF file
EJEdgar Jacoby
Edgar Jacoby
BWBerthold Wroblowski
Berthold Wroblowski
CBChristophe Buyck
Christophe Buyck
JNJean‐Marc Neefs
Jean‐Marc Neefs
CMChristophe Meyer
Christophe Meyer
HVHerman van Vlijmen
Herman van Vlijmen

18 October 2018
Verified
Book Chapter
Closed access
PDF file
EJEdgar Jacoby
Edgar Jacoby
JBJ. B. Brown
J. B. Brown

11 June 2020 in Future Drug Discovery
Verified
Journal Article
Open access
EJEdgar Jacoby
Edgar Jacoby
HVHerman Van Vlijmen
Herman Van Vlijmen
OQOlivier Querolle
Olivier Querolle
ISIan Stansfield
Ian Stansfield
LMLieven Meerpoel
Lieven Meerpoel
RARicardo Attar
Ricardo Attar
In the search for first-in-class NIK inhibitors for multiple myeloma, we discovered an azaindoline hit class generated from a biochemical NIK autophosphorylation high-throughput screening assay whi...

8 May 2018
Verified
Book Chapter
Closed access
PDF file
DDDaniela Digles
Daniela Digles
ACAndrei Caracoti
Andrei Caracoti
EJEdgar Jacoby
Edgar Jacoby